Advanced in Chromosome 8p Deletion

Hongyan Y. Tong

No. 79 Qingchun Road, 
Hangzhou, CN 
Advanced in Chromosome 8p Deletion
No. 79 Qingchun Road, 
Hangzhou, CN 
OverviewLocationsClinical Research

Overview

Hongyan Tong practices in Hangzhou, China. Tong is rated as an Advanced expert by MediFind in the treatment of Chromosome 8p Deletion. Their top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 182 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Chromosome 8p Deletion.

Locations

No. 79 Qingchun Road, Hangzhou, 310003, China
Other Locations
79# Qingchun Road, 310003, Hangzhou, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 3
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

182 Total Publications

Efficacy and safety of haploidentical hematopoietic stem cell transplantation combined with umbilical cord blood infusion in hematologic malignancies: a prospective phase II clinical trial.
Efficacy and safety of haploidentical hematopoietic stem cell transplantation combined with umbilical cord blood infusion in hematologic malignancies: a prospective phase II clinical trial.
Journal: Transplantation and cellular therapy
Published: July 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tong's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile